There is increasing evidence pointing toward an important role of heightened immune activation and inflammation in people living with HIV contributing to the development of non-AIDS comorbidities. This review aims to explore low bone mineral density (BMD) in HIV with a focus on the underlying mechanisms and relationships between the immune and skeletal systems.
INTRODUCTION
The advent of successful antiretroviral therapy (ART) for those with HIV infection has led to significant gains in life expectancy [1] . However, as the HIV-infected population ages, the burden of morbidity and mortality related to 'non-AIDS' comorbidities will increase. Low bone mineral density (BMD) and consequent fragility fractures are over-represented in people living with HIV (PLWH), with studies reporting an almost four-fold increase in prevalence of osteoporosis [2] and a 35% increased incidence in fragility fractures compared with the general population [3] [4] [5] .
Although traditional risk factors for low BMD are over-represented in PLWH alongside increased prevalence of the secondary causes of osteoporosis [6] [7] [8] , HIV itself has been shown to be independently associated with low BMD, even after correction for these risk factors [9 
THE IMMUNOSKELETAL INTERFACE AND ITS ROLE IN BONE HEALTH
Bone remodelling and BMD homeostasis is a continuous process balancing bone resorption by osteoclasts alongside bone formation by osteoblasts in a process known as coupling [11] . Osteoclasts derive from precursors within monocyte lineage. Osteoclast precursors express receptor activator nuclear factor NF-kB (RANK) when stimulated by macrophage colony stimulating factor [12] . RANK binds with receptor activator of NF-kB ligand (RANKL), a member of the TNF cytokine family expressed by osteoblasts [13] . Osteoclast differentiation and activity, known as osteoclastogenesis, is driven by this interaction between RANK and RANKL. The osteoclastogenic activity of RANKL is balanced by osteoprotegerin (OPG), expressed by osteoblasts. OPG acts as a decoy receptor for RANKL, hence downregulating osteoclastogenesis. The relative abundance of RANKL and OPG is thought to be integral to the maintenance of bone mass [14] .
In proinflammatory conditions, RANK, RANKL, and OPG can also be produced by cells of the immune system [14] [15] [16] [17] [18] , potentially affecting RAN-KL : OPG ratio. Indeed, chronic inflammation is shown to be involved in the pathogenesis of osteoporosis and fragility fractures in conditions such as rheumatoid arthritis (RA), periodontal disease, and perimenopausal osteoporosis [14, 15, [18] [19] [20] .
Proinflammatory cytokines are known to be potent stimulators of bone resorption via osteoclast signalling [18, 21] . In postmenopausal osteoporosis, the archetypal disease of bone, serum concentrations of IL-6 predict extent of bone loss [18] . Importantly, HIV-infected persons have 40-60% increased circulating IL-6 levels [22] and baseline IL-6 levels are independently associated with progression to osteopenia or osteoporosis in HIVinfected, ART-naïve patients [23] . IL-6 has also been shown to be strongly associated with all-cause mortality in PLWH in the Strategies for Management of Antiretroviral Therapy (SMART) study [24] . This study randomized HIV-infected patients to CD4 þ T-cell count-directed intermittent ART (i.e. stopping or deferring ART until CD4 þ count <350 cells/mm 3 ) vs. continuous ART. Although implicated in all-cause mortality, a SMART substudy did not find any association between IL-6 with BMD loss at hip or spine. Therefore, the role of IL-6 in bone remodeling in HIV-infected individuals remains unclear.
Some cytokines have functions that have been implicated in bone remodelling as shown in Table 1 [16, 18, 22, 23, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] 37 & ,38 & , [39] [40] [41] [42] [43] [44] [45] [46] [47] . Several of these cytokines are involved in regulation of osteoclastogenesis via upregulation of RANK expression or RANKL signalling [19, 23] . The proinflammatory cytokines TNFa and IL-1b have long been implicated in inflammatory conditions, such as postmenopausal osteoporosis and RA, where bone loss and destruction is a feature [33, [48] [49] [50] . In the SMART study, higher TNFa levels were associated with loss of spine BMD [31] . Another proinflammatory cytokine, IL-17, produced by Th17 T-cells, directly acts on stromal cells and osteoblasts to stimulate RANKL production and upregulate the expression of the proinflammatory cytokines TNFa and IL-1 [47] . The role of Th17 cells in the context of HIV-associated bone loss merits further investigation as IL-17 levels in those with HIV infection are elevated compared with noninfected study participants [43] .
Immune activation and inflammation in HIV: cross talk between B-cells, T-cells, and the RANK/RANKL/OPG axis
HIV infection is characterized by gut microbial translocation, thought to result from dysfunction in the gut barrier which leads to subsequent activation of both innate and adaptive immune pathways via monocyte activation [51] . Indeed, elevated levels of systemic bacterial cell wall product lipopolysaccharide (LPS) have been reported in those infected with HIV [51] . LPS was the first microbial product shown to induce bone resorption in vitro [52] , and to increase the number of osteoclast precursors in vivo [53] . LPS, a potent activator
KEY POINTS
There is a high prevalence of low BMD and an increased incidence of fractures in people living with HIV PLWH, with initiation of ART significantly contributing to BMD losses. Important cross-talk between the skeletal and immune systems underpins the maintenance of bone mass.
In PLWH, T-cell lymphopenia (including lower CD4 þ Tcell counts) and activation alongside B-cell dysfunction are increasingly implicated in the pathogenesis of low BMD in HIV.
Increased inflammation is recognized in HIV infection, with markers of inflammation associated with development of low BMD and osteoporotic fractures in the general population. Shown to stimulate osteoclast formation and bone loss [25] Impaired signalling between IFN-g and osteoblasts which normally downregulate RANKL expression [26] Also shown to suppress osteoclast differentiation by interfering with the RANKL-RANK signalling pathway [26] Polymorphism in IFN-g gene shown to associate with bone loss in elderly women [27] IL-6 Produced by immune cells and osteoblasts Higher IL-6 levels in HIV-infected persons [22] Estrogen deficiency potentiates secretion of IL-6 [29] Variable results in relation to bone loss in studies:
Strong predictor of bone loss in postmenopausal osteoporosis [18] Baseline IL-6 associated with progression to osteopaenia/ osteoporosis [23 & ] Polymorphisms in IL-6 gene which causes increased IL-6 levels associated with increased risk of osteoporotic fracture [30] IL-6 levels however not directly associated with BMD in SMART [31] IL-7 Key role in T and B-cell homeostasis [32] High circulating levels in HIV infection
Promotes RANKL production by T cells [33] Effects on bone undetermined
Involved in ovariectomy-induced bone loss in mice [34] Mediates T-cell re-expansion post-ART initiation [35] M-CSF Key cytokine involved in survival and differentiation of osteoclasts Changes in plasma RANKL did not correlate with bone resorption in this study
Higher baseline RANKL levels in HIV-infected ART-naïve patients [42, 43] .
TNFa Osteoclastogenic cytokine Increased in ART-naïve HIV-infected patients
Promotes RANKL production In the SMART study higher TNFa levels were associated with loss of BMD at LS [31] Inhibits osteoblast differentiation and activity Surrogate markers such as sTNFr1 and 2 levels have not been significantly associated with BMD [41] Key inflammatory cytokine
IL-17
Elevated levels in synovial fluids of RA patients Higher circulating levels in HIV-infected persons [43] .
Stimulates osteoclastogenesis [42] No studies on effects on bone directly but those with lower BMI have significantly higher levels of IL-17 in HIV-infected patients [43] .
Enhances expression of inflammatory cytokines
TNFa and IL-1 [47] Prominent bone loss in murine model mediated via upregulation of IL-17 and RANKL [44] IL-1b First cytokine shown to stimulate bone loss via stimulation of osteoclasts and inhibiting osteoblasts [45] Undetermined effects on bone in HIV Associated with postmenopausal osteoporosis [46] ART, antiretroviral therapy; LS, lumbar spine; M-CSF, macrophage colony stimulating factor.
of innate immune cells [51] , also promotes the expression of RANKL by osteoblasts in vitro, stimulating osteoclast differentiation [54] . Furthermore, injection of LPS into T-cell-and B-celldeficient mice can induce significant bone loss [55] . ,57], their impact on bone loss remains to be fully determined.
HIV infection is associated with an increase in the frequency of activated and exhausted CD4 þ and CD8 þ T cells, an increase in monocyte activation markers [58] , a reduction in B-cell numbers, an increase in the frequency of immature/transitional B cells, and increased circulating levels of inflammatory mediators [23] . 39, 40] . This imbalance may potentially bring about a shift in the RANKL: OPG ratio, which would favour osteoclastogenesis in HIVinfected individuals.
As major producers of OPG, B cells are recognized as important stabilisers of peak bone mass [14] [15] [16] . CD40-ligand, expressed by activated T cells, can upregulate B-cell OPG production via activation of the CD40 costimulatory receptor [14] .
Indeed, T-cell deficiency or loss of the CD40/CD40L costimulatory interaction in mice results in increased bone resorption and decreased bone mass [14] . In humans, osteopenia and fracture are prominent features of hyper IgM syndrome in which CD40L gene expression is altered [61] . Figure 1 outlines the immune-skeletal interface in HIV as described above.
In a recent cross-sectional study, Titanji et al. phenotype [37 & ]. In contrast, OPG expression by activated and exhausted B cells was lower in HIVþ individuals [37 & ]. These data support an immunocentric basis for HIV-associated bone loss with dysregulation of the OPG/RANKL axis toward osteoclastogenesis, driven by a significant imbalance in circulating B-cell RANKL and OPG expression. The impact of initiation of ART on these disturbances and whether these changes may ultimately contribute to the higher fracture rates seen in HIV-infected patients remains to be determined.
Activated T-cells also play an important role in osteoclastogenesis by producing cytokines such as TNFa, IL-1, IL-6, IL-17, and RANKL. To study the relationship between T-cell activation and BMD, Gazzola et al. [60] assessed 78 HIV-infected patients and found that those with low BMD had higher levels of T-cell activation [(CD4 þ , human leucocyte antigen DR (HLA-DRþ) and (CD8 þ , HLA-DRþ) T-cell subsets]. This activated T-cell phenotype was an independent predictor of low BMD. Furthermore, an increase in the frequency of activated T-cell population (CD28 þ /CD4 þ ) was also independently associated with low BMD in HIV þ patients [60] . Interestingly, in a recent study of a mouse model of RA, the administration with cytotoxic T-lymphocyte-associated protein 4 Immunoglobulin, an inhibitor of CD80/CD28 costimulation, and therefore a downregulator of T-cell activation, resulted in significant gains in bone volume [62] . The drug has recently been approved for use in immune-mediated conditions such as RA. It will be interesting to study how this inhibition of CD80/CD28 might affect bone volume in PLWH.
Antiretroviral therapy-associated bone loss: the role of immune reconstitution and ongoing immune activation and inflammation
The role of HIV as an independent predictor for low BMD and a risk factor for increased rate of fractures has been well documented [2,9 & ,63-66] . Additionally, multiple studies have shown a 2-6% loss in BMD in the first 2 years post-ART initiation [41, [67] [68] [69] . Increased levels of bone turnover markers (BTM), such as the bone resorption markers osteocalcin, and serum type 1 procollagen (P1NP), have been consistently observed with ART initiation in ART-naïve patients and have been associated with increased TNFa levels at ART initiation [9 & ,39,70] . Similarly, pre-ART HIV disease severity, measured by absolute CD4 þ T-cell counts and HIV RNA, have been associated with a greater subsequent loss of BMD at ART initiation [41, 71] . In a large longitudinal study, including 796 patients initiating ART, lower baseline CD4 þ T-cell count was strongly associated with greater loss of BMD over 96 weeks. Initiating ART at a CD4 þ count of less than 50 cells/ml resulted in 3% more BMD loss than those who initiated ART at a CD4 þ count of at least 500 cells/ml [71] . Lower baseline CD4 þ T-cell counts have also been associated with increased fracture prevalence in several HIV cohorts [71] [72] [73] [74] . These data suggest an important role for the degree of baseline immune activation and inflammation in bone loss and fracture risk in HIV and supports the benefits of earlier ART initiation.
Further support for the role of T cells in regulation of bone mass was reported by Ofotokun et al.
They reconstituted T-cell deficient, T-cell receptor beta (TCR-b) knockout mice with syngeneic CD3 þ T cells and found a significant increase in bone resorption and a decline in BMD following T-cell reconstitution [59] . The repopulated T cells produced increased levels of the proresorptive cytokines RANKL and TNFa, whereas OPG levels did not differ significantly, shifting the RANKL : OPG ratio toward one favouring bone loss. Finally, administering zoledronic acid (an antiresorptive bisphosphonate) at the time of T-cell transfer protected the TCR-b knockout mice from BMD loss at all sites [59] . Although this work provides important insight into the complex relationship between T cells and osteoclastic bone loss and simulates reexpansion of the T-cell compartment seen at ART initiation, HIV infection itself has complex host interactions and HIV viral proteins can also directly affect osteoclasts. This, as well as the direct effects of ART or varying regimes, were not explored in this model and require further investigation.
The effect of short course antiresorptive therapy in preventing bone loss in this study was encouraging as it could be used to prevent this irrecoverable bone loss in patients initiating ART. Two randomized control trials of bisphosphonates in preventing bone loss at ART initiation are currently underway; one using oral alendronate (https://clinicaltrials. gov/show/NCT02322099) and another, using intravenous zoledronate (https://clinicaltrials.gov/show/ NCT01228318). These studies will also examine the effects of such strategies on immune activation which will add to the reported work by Natsag et al. [75 & ] on the interaction between bisphosphonates and the immunoskeletal interface in improving BMD and decreasing fracture risk.
Further analyses of the effects of ART on immune activation, inflammation, and bone loss were recently reported by Brown et al. [38 & ]. In this study, changes in BMD with initiation of ART with a nucleotide reverse transcriptase inhibitor (NRTI) backbone including tenofovir disoproxil fumarate (TDF), combined with either protease inhibitors (either ritonavir-boosted atazanavir or darunavir) or the integrase strand transfer inhibitor raltegravir were examined. BMD declined significantly in all three treatments arms although BMD loss in the pooled protease inhibitor arms was greater than the raltegravir arm in both sites. Higher baseline sCD14, IL-6, and hs-CRP were all associated with greater bone loss over the 96 weeks at total hip. In addition, increases in both activated (CD4 þ ,CD38 þ , HLA-DRþ) and senescent CD4 þ T-cells (CD4 þ , CD28 À ,CD57 þ ) were also associated with bone loss at 96 weeks at the lumbar spine. These data suggest that the degree of underlying immune activation and inflammation at least in part determines extent of bone loss after ART initiation, independent of absolute CD4 þ T-cell counts, or HIV RNA levels [38 & ]. A further study exploring the relationship between BMD and inflammation at ART initiation in 106 ART-naïve patients, independent of regimen used (patients were randomized to either efavirenz or ritonavir boosted lopinavir in combination with zidovudine/lamivudine NRTI backbone for 24-48 weeks), reported that, although the inflammatory markers soluble tumour necrosis factor receptor 1 (sTNFR1) and sTNFR2, were suppressed through 24 weeks and sTNFR2 levels remained low through 96 weeks postinitiation [41] , there was a modest association between sTNFR2 and BMD loss at 96 weeks, which was no longer present when adjusted for baseline CD4 þ T-cell count. Data on bone biomarkers or other inflammatory cytokines were not available in this study, making it difficult to speculate on potential pathways through which BMD loss may have been mediated.
The NEAT001/ANRS European AIDS Treatment Network/French National Agency for Research on AIDS and Viral Hepatitis study groups reported on changes in BMD, alongside inflammatory and bone biomarkers, after 96 weeks of therapy with ritonavir boosted darunavir, in combination with either TDF/emtricitabine (standard therapy) or raltegravir (NRTI-sparing) [56 & ]. The study reported a significantly greater loss in BMD at all sites in those receiving standard therapy. Levels of the BTM (osteocalcin, 'Bone-Specific Alkaline Phosphatase' and P1NP), as well as RANKL were all increased at baseline in both treatment groups. There was a reduction, but no significant between-group difference, in RANKL at 48 weeks. However, those on NRTI-based therapy had significantly lower OPG levels. The resulting imbalance in the RANKL : OPG ratio therefore potentially contributing to the greater BMD loss seen in the standard group. The AIDS Clinical Trials Network (ACTG) study A5303, which examined BMD changes in 259 ART-naïve patients commencing therapy, comparing maraviroc with TDF [57] recently completed work on the immunology substudy and did not detect any significant associations between changes in immunological markers (measured at baseline and week 48) and percentage change in hip BMD. The completed results of this study are to be presented at the 2016 Conference on Retroviruses and Opportunistic Infections in Boston, MA.
Pre-ART levels of inflammation have been shown to impact the degree of postviral suppression, immune activation, and the development of serious non-AIDS comorbidities [22, [76] [77] [78] . However, although emerging evidence suggest that earlier ART initiation is beneficial, more studies are needed to examine the effects of persisting inflammation on bone health in those on long-term suppressive ART. The Stopping Atherosclerosis and Treating Unhealthy Bone With Rosuvastatin in HIV (SATURN-HIV) trial aimed to investigate the effect of low-dose rosuvastatin on bone health in persons on stable ART [79 & ]. Rosuvastatin decreases monocyte and lymphocyte activation in HIV [80] . Those randomized to rosuvastatin had a small but significant gain in hip BMD which was strongly associated with baseline and week 48 sTNFR2 levels supporting a potential beneficial effect on BMD mediated through modulation of inflammation [79 & ]. In a cross-sectional analysis of this parent study looking at the relationships between immune activation, inflammation, and bone health, including 142 participants with median CD4 þ T-cell counts of 604 cells/mm 3 and median duration of ART of 56 months, 23% had low BMD at hip, and 21% at lumbar spine. Those with low BMD at hip had unexpectedly lower IL-6 levels compared with those with normal BMD, whereas markers of CD4 þ T-cell activation were higher in those with low BMD at lumbar spine only. There were no significant correlations between BMD and BTMs with markers of T-cell activation, monocyte activation or inflammatory cytokines [81] . Similarly, 96-week data from the study did not show any significant associations with inflammatory markers or T-cell activation markers and BMD [82 & ]. However, numbers included were small, and therefore it may not have been adequately powered to detect such differences.
CONCLUSION
HIV infection, even in the setting of effective ART, is a state of immune activation and inflammation that can affect the expression and regulation of key immunological factors involved in bone remodelling. This complex interaction is likely influenced by other parameters, including traditional risk factors for low BMD and fragility fracture. Although there are data supporting the interplay between immune activation and chronic inflammation and the development of low BMD in HIV, longitudinal studies are needed to establish the role this may have in the pathogenesis of fragility fractures in PLWH.
